Compare Stocks: MTVA, NXTC, ATNM, and BCTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.05 +1.0%	$0.93	$0.74 ▼ $1.81	$33.01M	0.01	148,069 shs	344,634 shs
BCTX Briacell Therap	$3.39 -1.5%	$3.36	$2.60 ▼ $14.68	$29.93M	1.14	88,988 shs	59,169 shs
MTVA MetaVia	$1.48 -0.7%	$1.59	$0.97 ▼ $19.03	$7.69M	0.95	88,887 shs	58,955 shs
NXTC NextCure	$7.71 -6.1%	$3.89	$1.55 ▼ $15.74	$29.66M	1.26	492,966 shs	183,444 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	+30.42%	+12.81%	-11.11%	-38.46%
BCTX Briacell Therap	0.00%	-5.49%	-7.77%	+2.69%	-53.51%
MTVA MetaVia	0.00%	0.00%	-12.87%	+34.23%	-78.84%
NXTC NextCure	0.00%	+40.58%	+37.06%	-11.24%	+61.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.05 +1.0%	$0.93	$0.74 ▼ $1.81	$33.01M	0.01	148,069 shs	344,634 shs
BCTX Briacell Therap	$3.39 -1.5%	$3.36	$2.60 ▼ $14.68	$29.93M	1.14	88,988 shs	59,169 shs
MTVA MetaVia	$1.48 -0.7%	$1.59	$0.97 ▼ $19.03	$7.69M	0.95	88,887 shs	58,955 shs
NXTC NextCure	$7.71 -6.1%	$3.89	$1.55 ▼ $15.74	$29.66M	1.26	492,966 shs	183,444 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	+30.42%	+12.81%	-11.11%	-38.46%
BCTX Briacell Therap	0.00%	-5.49%	-7.77%	+2.69%	-53.51%
MTVA MetaVia	0.00%	0.00%	-12.87%	+34.23%	-78.84%
NXTC NextCure	0.00%	+40.58%	+37.06%	-11.24%	+61.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	376.19% Upside
BCTX Briacell Therap	1.00	Sell	N/A	N/A
MTVA MetaVia	2.00	Hold	$20.00	1,251.35% Upside
NXTC NextCure	2.25	Hold	$19.00	146.43% Upside

Current Analyst Ratings Breakdown

Latest MTVA, NXTC, ATNM, and BCTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/7/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	NXTC NextCure	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/18/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	0.94	N/A	N/A	$1.31 per share	0.80
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$2.31 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
MTVA MetaVia	-$12.97M	-$3.23	N/A	N/A	N/A	N/A	-209.67%	-107.91%	11/5/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)

Latest MTVA, NXTC, ATNM, and BCTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A
6/9/2026	Q3 2026	BCTX Briacell Therap	N/A	-$0.99	N/A	-$0.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
BCTX Briacell Therap	N/A	7.07	7.07
MTVA MetaVia	N/A	2.06	2.06
NXTC NextCure	N/A	3.47	3.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
BCTX Briacell Therap	15.42%
MTVA MetaVia	1.37%
NXTC NextCure	42.65%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
BCTX Briacell Therap	0.74%
MTVA MetaVia	0.60%
NXTC NextCure	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.44 million	29.32 million	Optionable
BCTX Briacell Therap	8	8.70 million	8.64 million	No Data
MTVA MetaVia	8	5.16 million	5.13 million	N/A
NXTC NextCure	90	3.61 million	3.18 million	No Data

MTVA, NXTC, ATNM, and BCTX Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for NextCure Q3 Earnings

August 16 at 1:15 AM | americanbankingnews.com

Wall Street Zen Upgrades NextCure (NASDAQ:NXTC) to "Hold"

August 15 at 1:53 AM | americanbankingnews.com

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

August 10, 2026 | prnewswire.com

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 36,303 Shares of Stock

August 4, 2026 | insidertrades.com

Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $17,050.00 in Stock

July 30, 2026 | insidertrades.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB

July 23, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for ...

July 21, 2026 | caledonianrecord.comC

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB

July 21, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 21, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

July 14, 2026 | prnewswire.com

New biotech Avere plots listing via NextCure merger

July 14, 2026 | pharmaphorum.comP

NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders

July 14, 2026 | aol.comA

NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement

July 14, 2026 | blockonomi.com

NextCure announces reverse merger with privately held Avere

July 14, 2026 | seekingalpha.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 14, 2026 | prnewswire.com

NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

July 14, 2026 | globenewswire.com

3 Cancer Stocks to Watch as Oncology Innovation Accelerates

July 8, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, NXTC, ATNM, and BCTX Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.05 +0.01 (+0.96%)

As of 04:00 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Briacell Therap NASDAQ:BCTX

$3.39 -0.05 (-1.45%)

As of 04:00 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

MetaVia NASDAQ:MTVA

$1.48 -0.01 (-0.67%)

As of 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

NextCure NASDAQ:NXTC

$7.71 -0.50 (-6.09%)

As of 04:00 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTVA, NXTC, ATNM, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTVA, NXTC, ATNM, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTVA, NXTC, ATNM, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, NXTC, ATNM, and BCTX Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Briacell Therap NASDAQ:BCTX

MetaVia NASDAQ:MTVA

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTVA, NXTC, ATNM, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTVA, NXTC, ATNM, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTVA, NXTC, ATNM, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA, NXTC, ATNM, and BCTX Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Briacell Therap NASDAQ:BCTX

MetaVia NASDAQ:MTVA

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools